| Literature DB >> 6861259 |
C G Beardwell, A C Hindley, P M Wilkinson, I D Todd, G G Ribeiro, D Bu'Lock.
Abstract
The combination of trilostane 960 mg daily and either dexamethasone 0.5 mg b.d. or hydrocortisone 10 mg b.d. has been used to treat advanced metastatic breast cancer in post-menopausal women. Twenty-three patients had assessable disease and received treatment for a minimum of 8 weeks. Six (26%) showed an objective response and three (13%), stabilisation of previously progressive disease, sustained for at least 3 months. Side-effects were mainly gastrointestinal. Biochemical studies suggest that the mechanism of action may be inhibition of conversion of androstenedione to oestrone.Entities:
Mesh：
Substances：
Year: 1983 PMID： 6861259 DOI： 10.1007/bf00255752
Source DB: PubMed Journal: Cancer Chemother Pharmacol ISSN： 0344-5704 Impact factor: 3.333